If APOC3 is found to be a key factor in GBS-related inflammation, it could open up possibilities for developing targeted therapies aimed at modulating APOC3 or its effects, potentially reducing the severity of inflammation and the progression of GBS. Here, APOC3 is linked to Guillain-Barre syndrome.